EGFR and hepatocellular carcinoma: In summary, our data demonstrated that DDOST, a key noncatalytic subunit of OST, played an oncogenic role in HCC and decreased the response to lenvatinib and immunotherapy by promoting N-glycosylation of EGFR and PD-L1 (Fig. 9).